BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 17509958)

  • 1. Vascular endothelial growth factor, lipoporotein-associated phospholipase A2, sP-selectin and antiphospholipid antibodies, biological markers with prognostic value in pulmonary hypertension associated with chronic obstructive pulmonary disease and systemic lupus erithematosus.
    Tanaseanu C; Tudor S; Tamsulea I; Marta D; Manea G; Moldoveanu E
    Eur J Med Res; 2007 Apr; 12(4):145-51. PubMed ID: 17509958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of nailfold capillaroscopy in systemic lupus erythematosus: correlation with endothelial cell activation markers and disease activity.
    Kuryliszyn-Moskal A; Ciolkiewicz M; Klimiuk PA; Sierakowski S
    Scand J Rheumatol; 2009; 38(1):38-45. PubMed ID: 18991188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating endothelial cells, endothelial apoptosis and soluble markers of endothelial dysfunction in patients with systemic lupus erythematosus-related vasculitis.
    Kluz J; Kopeć W; Jakobsche-Policht U; Adamiec R
    Int Angiol; 2009 Jun; 28(3):192-201. PubMed ID: 19506538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum levels of vascular endothelial growth factor in children and adolescents with systemic lupus erythematosus.
    Heshmat NM; El-Kerdany TH
    Pediatr Allergy Immunol; 2007 Jun; 18(4):346-53. PubMed ID: 17346298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of serum vascular endothelial growth factor and nail fold capillaroscopy changes in systemic lupus erythematosus with and without cutaneous manifestations.
    Moneib HA; Salem SA; Aly DG; Khedr HT; Wafaey HA; Hassan HE
    J Dermatol; 2012 Jan; 39(1):52-7. PubMed ID: 21950586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impaired control of the tissue factor pathway of blood coagulation in systemic lupus erythematosus.
    Adams MJ; Palatinus AA; Harvey AM; Khalafallah AA
    Lupus; 2011 Dec; 20(14):1474-83. PubMed ID: 21993387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of antibodies to beta2-glycoprotein I in systemic lupus erythematosus and their association with antiphospholipid antibody syndrome criteria: a single center study and literature review.
    Bruce IN; Clark-Soloninka CA; Spitzer KA; Gladman DD; Urowitz MB; Laskin CA
    J Rheumatol; 2000 Dec; 27(12):2833-7. PubMed ID: 11128672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulmonary arterial hypertension in SLE: what do we know?
    Prabu A; Gordon C
    Lupus; 2013 Oct; 22(12):1274-85. PubMed ID: 24098000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus].
    Formiga F; Moga I; Canet R; Pac M; Mitjavila F; Pujol R
    Rev Clin Esp; 1996 Nov; 196(11):734-6. PubMed ID: 9132835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Soluble P-selectin - a marker of platelet activation and vessel wall injury: increase of soluble P-selectin in plasma of patients with myocardial infarction, massive atherosclerosis and primary pulmonary hypertension].
    Semenov AV; Kogan-Ponomarev MIa; Ruda MIa; Komarov AL; Panchenko EP; Chazova IE; Mazurov AV
    Ter Arkh; 2000; 72(4):15-20. PubMed ID: 10833791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating vascular endothelial growth factor and systemic inflammatory markers in patients with stable and exacerbated chronic obstructive pulmonary disease.
    Valipour A; Schreder M; Wolzt M; Saliba S; Kapiotis S; Eickhoff P; Burghuber OC
    Clin Sci (Lond); 2008 Oct; 115(7):225-32. PubMed ID: 18307413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of selected endothelial activation markers in patients with systemic lupus erythematosus.
    Kuryliszyn-Moskal A; Klimiuk PA; Ciolkiewicz M; Sierakowski S
    J Rheumatol; 2008 Jul; 35(7):1307-13. PubMed ID: 18484695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus.
    Bertolaccini ML; Atsumi T; Escudero Contreras A; Khamashta MA; Hughes GR
    J Rheumatol; 2001 Dec; 28(12):2637-43. PubMed ID: 11764209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies.
    Horbach DA; van Oort E; Donders RC; Derksen RH; de Groot PG
    Thromb Haemost; 1996 Dec; 76(6):916-24. PubMed ID: 8972011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome.
    Tektonidou MG; Sotsiou F; Nakopoulou L; Vlachoyiannopoulos PG; Moutsopoulos HM
    Arthritis Rheum; 2004 Aug; 50(8):2569-79. PubMed ID: 15334471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Higher Incidence of Pulmonary Hypertension in Antiphospholipid Antibody Positive Lupus.
    Ware D; Sharma V; Kalekar L; Kamble A; Mahajan A; Gokhale Y
    J Assoc Physicians India; 2015 Apr; 63(4):17-20. PubMed ID: 26591164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombin generation measured ex vivo following microvascular injury is increased in SLE patients with antiphospholipid-protein antibodies.
    Musiał J; Swadźba J; Jankowski M; Grzywacz M; Bazan-Socha S; Szczeklik A
    Thromb Haemost; 1997 Oct; 78(4):1173-7. PubMed ID: 9364980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet activation rather than endothelial injury identifies risk of thrombosis in subjects positive for antiphospholipid antibodies.
    Jy W; Tiede M; Bidot CJ; Horstman LL; Jimenez JJ; Chirinos J; Ahn YS
    Thromb Res; 2007; 121(3):319-25. PubMed ID: 17582471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments.
    Charniot JC; Khani-Bittar R; Albertini JP; Giral P; Cherfils C; Cosson C; Guillerm E; Leprince P; Gandjbakhch I; Bonnefont-Rousselot D
    Int J Cardiol; 2013 Sep; 168(1):132-8. PubMed ID: 23103135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pulmonary arterial hypertension in systemic lupus erythematosus].
    Arnaud L; Agard C; Haroche J; Cacoub P; Piette JC; Amoura Z
    Rev Med Interne; 2011 Nov; 32(11):689-97. PubMed ID: 21376432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.